Table 1.
Patient Characteristics Stratified by Tyrosine Kinase Inhibitor (TKI) Continuation
| TKI Discontinuation | TKI Continuation | P value | ||||
|---|---|---|---|---|---|---|
| Number | % | Number | % | |||
| Total | 21 | 37 | ||||
| Age (y) | 0.729 | |||||
| <65 | 18 | 85.7% | 29 | 78.4% | ||
| Sex | 0.702 | |||||
| Female | 13 | 61.9% | 21 | 56.8% | ||
| Smoker | 0.741 | |||||
| Non-smoker | 16 | 76.2% | 30 | 81.1% | ||
| ECOG performance status | ||||||
| 0-1 | 21 | 100.0% | 37 | 100.0% | ||
| Histology | 0.743 | |||||
| Adenocarcinoma | 20 | 95.2% | 34 | 91.9% | ||
| Squamous carcinoma | 1 | 4.8% | 2 | 5.4% | ||
| Adenosquamous carcinoma | 0 | 0.0% | 1 | 2.7% | ||
| Mutation Type | 0.437 | |||||
| Exon 19 deletion | 13 | 61.9% | 19 | 51.4% | ||
| L858R | 8 | 38.1% | 18 | 48.6% | ||
| Line of TKI | 0.788 | |||||
| 1 | 16 | 76.2% | 27 | 73.0% | ||
| >=2 | 5 | 23.8% | 10 | 27.0% | ||
| Brain metastases | <0.001 | |||||
| Yes | 19 | 90.5% | 5 | 13.5% | ||
| Number of Extracranial Lesions | 1.000 | |||||
| <=6 | 17 | 81.0% | 30 | 81.1% | ||
| Scan comparison with immediate prior scan | 0.016 | |||||
| Progressive Disease | 11 | 52.4% | 8 | 21.6% | ||
| Stable Disease | 10 | 47.6% | 29 | 78.4% | ||
| Progressive site | 0.268 | |||||
| Original Site | 13 | 61.9% | 28 | 75.7% | ||
| New Site | 8 | 38.1% | 9 | 24.3% | ||
| Prior progression-free survival (months) | 0.585 | |||||
| Long | 9 | 42.9% | 20 | 54.1% | ||
| Short | 12 | 57.1% | 17 | 45.9% | ||
| Treatment after progression | ||||||
| Immediate Chemotherapy | 0.040 | |||||
| Yes | 10 | 47.6% | 8 | 21.6% | ||
| Chemotherapy at any time postprogression | 0.760 | |||||
| Yes | 15 | 71.4% | 25 | 67.6% | ||
| Definitive primary local therapy | 0.402 | |||||
| Yes | 1 | 4.8% | 5 | 13.5% | ||
| Definitive metastatic local therapy | 0.148 | |||||
| Yes | 0 | 0.0% | 5 | 13.5% | ||
| Definitive local therapy to any site | 0.036 | |||||
| Yes | 1 | 4.8% | 10 | 27.0% | ||